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Cardiac medications and their association with cardiovascular
events in incident dialysis patients: Cause or effect?
Background. There are no large randomized, controlled tri-
als evaluating the efficacy of common cardioprotective medi-
cations on cardiovascular outcomes in the dialysis population.
We aimed to determine the association between cardioprotec-
tive medications and a composite end point of cardiovascular
events or death in an incident dialysis cohort.
Methods. Medicare claims data were utilized to determine
outcomes in participants of the Dialysis Morbidity and Mor-
tality Wave 2 cohort. Information was gathered at baseline re-
garding demographics, comorbidities, medication use, and lab
data. Cox proportional hazard models were developed to deter-
mine the association between cardioprotective medication use
at baseline and the subsequent development of a composite of
cardiovascular events or death.
Results. Two thousand two hundred thirty-four of 3044 in-
dividuals experienced a cardiovascular event or death. Use of
the following medications at baseline was associated with an in-
creased event rate: nitrates, antiplatelet agents, and warfarin.
There was no association between the use of angiotensin-
converting enzyme inhibitors, beta-blockers, or 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
and a composite cardiovascular outcome or death. Only use of
a calcium channel blocker at baseline was associated with a re-
duced risk of events. This beneficial association did not persist
when death was excluded as an outcome. Many of the associa-
tions observed varied substantially depending on the outcome
utilized.
Conclusion. Use of cohort data to determine an association
between medication use and outcome is difficult because the in-
dication for the medication confounds the observed association.
Before widespread practice changes, rigorous clinical trials of
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common cardioprotective medications on cardiovascular mor-
bidity and mortality in dialysis should be performed.
The incidence of cardiovascular disease in dialysis pa-
tients is significantly greater than that of age- and gender-
matched control patients who are not on dialysis [1]. It
is estimated that cardiovascular disease (CVD) accounts
for 44% of end-stage renal disease (ESRD) mortality [2].
Despite this excessive mortality, there have been no ran-
domized, controlled trials to assess the benefit of common
cardioprotective medications in dialysis patients. Trials
in the general population exclude those with pre-existing
kidney disease. Whether the benefits of these therapies
can be extrapolated to ESRD patients remains unclear.
Recently, a number of authors have attempted to de-
lineate the association between medication use and the
occurrence of cardiovascular disease or death. Some au-
thors have reported a protective association between
calcium channel blockers [3], angiotensin-converting in-
hibitors [4, 5], and 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitors [6] and all-cause
mortality, while others have not found these protec-
tive associations [7, 8]. For a convincing argument to be
made that a particular medication reduces cardiovascu-
lar events and death, the benefits of a therapy should not
only be demonstrated by reductions in all-cause mortal-
ity, but also it should be demonstrated that cardiovascular
events are decreased as well, because this is the pathway
through which deaths are averted. If, however, the as-
sociations are sensitive to the outcome utilized, it may
suggest that the observed benefits are confounded. Indi-
cation bias results as therapies are not randomly initiated,
but are started as a treatment for an underlying condi-
tion [9]. Utilizing registry and cohort data it is difficult to
determine the underlying indication resulting in a ther-
apy. Despite attempts at correction through multivariate
analysis the resulting associations remain confounded, as
many of these therapeutic indications are unmeasured
and unknown.
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Given these discrepancies in the literature we under-
took an analysis of the Dialysis Morbidity and Mortality
Study, Wave 2 substudy after linking it to Medicare claims
files to determine the association between the use of
cardioprotective medications and a composite end point
of cardiovascular disease (myocardial infarction, conges-
tive heart failure, peripheral vascular disease, and stroke)
and all-cause mortality. In addition, we determined their
association with the primary and secondary prevention
of individual cardiovascular end points.
METHODS
The Dialysis Morbidity and Mortality Study (DMMS)
was an observational study of a random sample of United
States dialysis patients. The Wave 2, a substudy of the
DMMS, was a prospective cohort of incident dialysis pa-
tients. It comprised all patients initiating peritoneal dial-
ysis and one fifth of those initiating hemodialysis from
1996 to 1997. Participants were included if they survived
60 days after initiating dialysis. Participants of the Wave 2
study were linked electronically through a unique identi-
fier with the United States Renal Data System (USRDS)
to ascertain study outcomes.
Data for the Wave 2 study were collected by trained
dialysis center personnel with the use of interviews
and chart abstraction. In addition to demographics, in-
formation was collected on clinical variables (smok-
ing, weight, blood pressure), comorbidities, medication
use (maximum of 15 abstracted), and laboratory re-
sults. Utilizing this data we determined an individual’s
use of cardioprotective medications through a compar-
ison of the patient’s recorded medications with a list
of generic and brand name medications, including com-
mon variations in spelling. The following classes of
drugs were identified: angiotensin-converting enzyme in-
hibitors (ACEI), calcium channel blockers (CCB), beta-
blockers (BB), nitrates, alpha-blockers, central acting
agonists, vasodilators, HMG-CoA reductase inhibitors
(statins), antiplatelet agents, and warfarin.
The primary outcome of this study was to identify the
association between common cardioprotective medica-
tions and the incidence of a composite cardiovascular out-
come [any of the following: myocardial infarction (MI),
congestive heart failure (CHF), cerebrovascular accident
(CVA), peripheral vascular disease (PVD), or death].
Secondary analyses aimed to determine the association
between cardioprotective drug use and a composite of
cardiovascular events with death censored as an outcome,
death alone, and the primary and secondary prevention of
myocardial infarctions, CHF, and PVD. We were unable
to assess the association between cardioprotective med-
ication use and cerebrovascular accidents, because few
events had occurred at the time of our analysis. Finally,
to test the sensitivity of including CHF events in our com-
posite end point, we performed an additional subgroup
analysis excluding CHF events, looking at time to MI,
PVD, CVA, or death.
Outcomes were assessed through Medicare claims data
submitted to the USRDS. The following events were
identified: myocardial infarction, congestive heart failure,
stroke, peripheral vascular disease, and death. The fol-
lowing International Classification of Diseases, Ninth Re-
vision (ICD-9-CM) codes were utilized to identify events:
myocardial infarctions 410.xx (except 410.×2), conges-
tive heart failure (402.×1, 4.25.xx, 428.xx, 518.4 and
398.01), stroke (430.xx, 431.xx, 432.xx, 433.xx, 434.xx),
and peripheral vascular disease [440.xx to 444.xx, except
443.0 and 447.xx (except 447.0, 447.6, 447.8, and 447.9)].
Events were ascertained through December 1999.
Statistical analysis
We utilized Cox proportional hazard models to deter-
mine the association between cardiovascular drug use
and the development of a composite cardiovascular out-
come. Time to event was defined as the time from the
initiation of the study until first event, death, or study
end. For disease-specific outcomes, individuals were con-
sidered to have an outcome only if they developed the
specific disease of interest.
As medication use is often confounded by indication,
we performed subgroup analyses to determine if the as-
sociations we were detecting were true or simply reverse
causation [10]. We determined hazard ratios in those with
a prior history of events and in those without a prior
history.
When the analysis was stratified by primary or sec-
ondary prevention, individuals without a documented
history of the outcome were considered in the primary
prevention model, whereas those with a prior history of
the outcome were considered in the secondary preven-
tion model. For all secondary analyses, individuals were
death censored. Individuals continued to be included in
the analyses once they received a transplant. To deter-
mine the impact of transplant on outcomes, we performed
additional analyses with time to transplant included as
a time-dependent model, as well as a model in which
individuals were censored at transplant. To test propor-
tionality an interaction term between a time-dependent
variable and each drug was entered into the final model.
In addition, the full model was run with follow-up time
broken into strata to further evaluate proportionality.
Finally, we performed sensitivity analysis to determine
the impact of excluding those without Medicare as a pri-
mary insurer. We used the outcome of death because the
reporting of this event is independent of Medicare sta-
tus. We calculated the effect of cardioprotective medi-
cations on death, including and excluded those without
Medicare. In addition, we constructed a model using an
indicator variable for Medicare status to determine if our
results differed in those with and without Medicare.
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Table 1. Baseline characteristics comparing included and excluded subsets
Included compared to excluded participants
All No Yes
N = 3941 N = 897 N = 3044 P valuea Odds ratiob P valueb
Medications
ACE inhibitors 25.5 24.1 25.9 .28 1.09 .39
Calcium blockers 52.5 49.9 53.3 .08 1.11 .39
Beta-blockers 19.2 17.4 19.7 .12 1.08 .47
Nitrates 16.9 10.7 18.7 <.0001 1.20 .19
Vasodilators 6.5 6.0 6.6 .51 1.00 .99
Statins 10.0 10.0 10.0 .94 .82 .16
Anti-platelet agents 19.0 13.0 20.8 <.0001 1.32 .03
Warfarin 5.6 4.1 6.0 .03 1.08 .69
Comorbid conditions
Myocardial infarction 20.6 21.0 20.5 .78 .73 .01
Congestive heart failure 39.7 33.8 41.4 <.0001 1.13 .24
Cerebrovascular accident 15.2 15.9 15.0 .50 .84 .17
Peripheral vascular disease 23.5 22.5 23.8 .44 .89 .33
Diabetes mellitus 51.8 49.1 52.7 .06 .98 .91
Primary renal disease
Diabetes mellitus 43.0 39.1 44.2 .01 1.28 .17
Hypertension 25.9 23.9 26.5 .12 1.12 .38
Glomerulonephritis 8.4 8.9 8.3 .52 1.31 .11
Other/unknown 22.7 28.1 21.1 <.0001 Ref
Age years 58.6 ± 15.8 52.1 ± 16.0 60.3 ± 15.3 <.0001 1.03 <.0001
Race
White 61.9 54.1 64.2 <.0001 1.27 .12
Black 28.9 30.1 28.6 .37 1.21 .24
Gender
Male 52.1 46.7 53.7 .0002 1.22 .02
Mode of dialysis
Hemodialysis 50.2 48.6 50.7 .28 .89 .20
Blood pressure mm Hg
Systolic 146.8 ± 21.2 146.2 ± 20.6 147.0 ± 21.4 .39 1.00 .64
Diastolic 79.5 ± 12.2 81.5 ± 12.1 79.0 ± 12.2 <.0001 1.00 .79
aContinuous parameters are compared with a t test. Categorical parameters are compared using the v 2 test.
bUsing a logistic regression model with the presence of absence of being included in our study as dependent variable, with all the baseline parameters shown in the
first column as covariates.
RESULTS
A total of 4024 participants were included in the Wave
2 study. Of these, 83 were missing a valid USRDS iden-
tifier and excluded, leaving 3941 individuals. Because
our outcomes relied on Medicare claims data, we fur-
ther excluded 643 individuals who were not Medicare
recipients at the initiation of the of the Wave 2 study,
leaving 3298 individuals. An additional 254 individuals
were excluded because of missing demographic or co-
variate information, leaving a total of 3044 (75.6%) ana-
lyzable individuals.
The characteristics of those included and excluded in
our study are outlined in Table 1. The last two columns
in Table 1 demonstrate the odds of being included in our
study based on baseline characteristics. Those included
in our study were more likely to be older, male gender,
on antiplatelet agents, and have a lower probability of
having had a previous MI compared with those excluded
from our study.
Table 2 demonstrates the baseline characteristics in the
Medicare-only cohort. Cardiovascular disease was more
prevalent in those on nitrates, vasodilators, anti-platelet
agents, and warfarin at baseline. To determine if those
enrolled in the Medicare program had a different preva-
lence of cardiovascular disease compared with those not
enrolled in Medicare, we entered an indicator variable
into our logistic regression model. The results of this
model suggested that the prevalence of coronary artery
disease at baseline was similar in those included and ex-
cluded from our analysis [odds ratio (OR) 0.86, 95% CI
70–1.06].
Sensitivity analysis
To determine the effect of excluding those without
Medicare as the primary payer we constructed two mod-
els. In both models, death was the outcome of interest. In
the first model we included the entire cohort, and in the
second we included only those with Medicare as the pri-
mary payer. There were not any significant differences
in either the direction or the magnitude of the associa-
tion between cardioprotective drugs and death. In addi-
tion, we constructed a third model in which we utilized
an indicator variable for Medicare status to determine
if this subgroup was significantly different than the en-
tire cohort. Addition of Medicare status to this model
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Table 2. Characteristics of study subjects with and without cardiovascular disease at baseline
Cardiovascular disease at baselinea
All No Yes Odds ratioc
N = 3044 N = 1290 N = 1753 P valueb N = 3044 P valuec
Medications
ACE inhibitors 25.7 25.4 26.2 .63 1.05 .60
Calcium blockers 53.1 54.7 52.3 .18 1.03 .77
Beta-blockers 19.6 19.8 19.7 .92 .97 .79
Nitrates 18.46 6.0 28.1 <.0001 3.49 <.0001
Vasodilators 6.6 5.0 7.8 .002 1.53 .02
Statins 9.9 9.0 10.7 .13 1.01 .95
Anti-platelet agents 20.7 10.9 28.0 <.0001 1.93 <.0001
Warfarin 6.0 2.3 8.8 <.0001 3.65 <.0001
Comorbid conditions
Myocardial infarction 20.6
Congestive heart failure 41.3
Cerebrovascular accident 15.1
Peripheral vascular disease 24.0
Diabetes mellitus 52.6 37.4 63.9 <00001 2.4 <.0001
Primary renal disease
Diabetes mellitus 44.0 31.4 53.6 <.0001 1.32 .12
Hypertension 26.5 29.0 24.6 .007 1.08 .56
Glomerulonephritis 8.3 12.8 4.9 <.0001 .81 .24
Other/unknown 21.3 26.9 16.9 <.0001 Ref
Age years 60.1 ± 15.7 54.0 ± 16.2 64.9 ± 12.7 <.0001 1.05 <.0001
Race
White 64.1 59.6 67.5 <.0001 1.30 .11
Black 28.7 31.7 26.2 .001 1.25 .20
Gender
Male 53.7 52.9 54.3 .46 1.18 .06
Mode of dialysis
Hemodialysis 50.7 44.8 55.0 <.0001 1.27 .01
Blood pressure mm Hg
Systolic 147.2 ± 21.3 146.8 ± 20.3 147.0 ± 22.2 .78 1.0 .29
Diastolic 79.2 ± 12.1 81.9 ± 11.8 76.8 ± 12.0 <.0001 1.0 .96
aCardiovascular disease is defined as coronary artery disease, congestive heart failure, cerebrovascular disease, or peripheral vascular disease at baseline.
bContinuous parameters are compared using a t test. Categorical parameters are compared using the v 2 test.
cUsing a logistic regression model with the presence of absence of cardiovascular disease as dependent variable, with all the baseline parameters shown in the first
column as covariates.
demonstrated no association between primary insurance
source and the outcome of death [hazards ratio (HR)
1.00, 95% CI .87–1.14]. All subsequent analyses included
only those with Medicare as the primary insurance source.
Cardiovascular disease
Table 3 demonstrates the association between the use
of cardioprotective medication at study entry and the sub-
sequent development of our primary end point. Factors
significantly associated with an increased risk of our pri-
mary outcome on multivariate analysis were the use of ni-
trates, anti-platelet agents, and warfarin at baseline. Only
baseline use of calcium channel blockers was associated
with a decreased risk of the composite end point of death
or cardiovascular events.
Medications
In multivariate analysis, use of any CCB at study en-
try was associated with a significant 10% reduction in the
composite end point of cardiovascular disease or death.
These results persisted when CHF was excluded as an
event in the primary analysis, and when the outcome was
restricted to only death. However, when death was cen-
sored as an outcome, CCB use was no longer associated
with a reduction in cardiovascular events; logistic regres-
sion analysis determining associations between baseline
medication use and a previous history of an MI demon-
strated that CCB use was inversely associated with a pre-
vious MI (HR .77, 95%CI .62–.95), suggesting that CCB
were preferentially underprescribed in those with a pre-
vious history of MI. Figure 1 demonstrates the association
between baseline CCB use and our secondary outcomes.
There was no association between CCB use and either
MI or PVD. CCB use was associated with a decreased
risk of recurrent heart failure.
ACEIs were used in 25.5% of the Medicare cohort at
baseline. Use of ACEI was not different among those with
and without a history of cardiovascular disease at base-
line. Figure 2 demonstrates the affect of baseline ACEI
use and the subsequent development of cardiovascular
disease. We were unable to demonstrate in any of our
models an association between ACEI use at baseline and
the development of cardiovascular events or death.
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Table 3. Baseline associations of the primary composite outcomea
Hazards 95% Confidence P
Ratiob Interval value
Medications
ACE-inhibitors 0.99 0.90–1.09 0.84
Calcium blockers 0.90 0.82–0.98 0.02
Beta-blockers 0.95 0.85–1.06 0.38
Nitrates 1.33 1.20–1.49 <0.01
Vasodilators 1.03 0.87–1.22 0.72
Statins 0.87 0.76–1.01 0.06
Anti-platelet agents 1.13 1.02–1.25 0.02
Warfarin 1.29 1.09–1.52 0.00
Comorbid conditions
Myocardial infarction 1.10 0.98–1.22 0.09
Congestive heart failure 1.45 1.32–1.59 <0.01
Cerebrovascular accident 1.01 0.90–1.14 0.82
Peripheral vascular disease 1.27 1.15–1.40 <0.01
Diabetes mellitus 1.11 0.95–1.30 0.18
Primary renal disease
Diabetes mellitus 1.19 1.01–1.42 0.04
Hypertension 0.95 0.83–1.08 0.41
Glomerulonephritis 0.82 0.67–0.99 0.04
Other/unknown ref
Age years 1.02 1.02–1.03 <0.01
Race
White 1.23 1.04–1.46 0.02
Black 1.08 0.90–1.29 0.42
Gender
Male 1.00 0.92–1.09 0.99
Mode of dialysis
Hemodialysis 0.97 0.88–1.06 0.48
Blood pressure mm Hg
Systolic 1.00 1.00–1.00 0.13
Diastolic 0.99 0.99–1.00 0.03
aThe primary outcome is the time to the first cardiovascular event (admission
for myocardial infarction, congestive heart failure, cerebrovascular accident, or
peripheral vascular disease) after study initiation, or death.
bUsing a proportional hazards model with all the baseline parameters shown
in the first column as covariates.
The use of statins occurred in only 9.9% of the Wave 2
population. Use of statins was not significantly different
in those with and without a history of previous cardio-
vascular disease. However, in a logistic regression model
with previous MI as the dependent variable, statin use
was 37% more likely to have been used in those with a
previous history of MIs (HR 1.37, 95% CI 1.05–1.79). In
Cox proportional hazards model, statin use was associ-
ated with a nonsignificant 13% reduction in the compos-
ite end point of death or cardiovascular event (P = .06)
(Fig. 3). The beneficial association with statins was more
evident when CHF was excluded as an event in the pri-
mary outcome. In addition, the magnitude of association
increased when only mortality was considered as an end
point (HR 0.74 95% CI .62–.87). Similar to CCBs, the
effect of statins on events appears to be predominately
from a reduction in death, because neither overall nor
individual cardiovascular events were reduced in those
patients on statins. Unexpectedly, there was a nonsignifi-
cant 32% increase in the incidence of primary CHF events
(HR 1.32, 95% CI .99–1.76). This increase in risk may be
attributable to the increased prevalence of previous MIs
among statin users.
Beta-blockers were used in about 20% of the Wave
2 study population. Use of beta-blockers was similar
irrespective of past cardiovascular history. However,
beta-blockers were used more frequently in those with
a previous history of MIs (HR 1.38, 95% CI 1.12–1.71).
As Figure 4 demonstrates, there was no association be-
tween baseline use of beta-blockers and the subsequent
development of any outcome.
The use of anti-platelet agents was 93% more common
in those with a previous history of cardiovascular disease,
even after correcting for baseline confounders (Table 2).
Use of anti-platelet agents was associated with a signifi-
cant 13% increase in the composite end point of death
or cardiovascular event (HR 1.13, 95% CI 1.02–1.25)
(Fig. 5). In addition, when death was censored as an
outcome, anti-platelet use was associated with a 15% in-
creased risk of cardiovascular events (HR 1.15, 95% CI
1.02–1.31).
Finally, it is well described that individuals on peri-
toneal dialysis tend to be healthier and subsequently
more likely to receive a transplant compared with those
on hemodialysis. This differential transplant rate may
have introduced bias into our observed results. We con-
structed two additional models in which an individual’s
transplant status was modeled as a time-dependent vari-
able, and in which individuals were censored at the time
of transplantation. None of the associations observed be-
tween medication use and cardiovascular events or death
changed significantly in either of these models (data not
shown).
Proportionality testing was insignificant for each drug.
In addition, results did not change when follow-up time
was stratified by years after follow-up.
CONCLUSION
Our results demonstrate that in a cohort of incident
Medicare dialysis patients the prevalence of cardiovas-
cular disease at baseline is high, and the incidence of ad-
ditional cardiovascular events or death after a median
duration of 2.7 years was 73.4%. Use of CCBs at base-
line was associated with a 10% lower incidence of the
primary end point. However, this observation was de-
pendent on the outcome used. Additionally, it appears
that CCBs are less frequently used in those with a prior
history of MI. Additionally, we demonstrated that the
use of statins at baseline was associated with a reduced
risk of all- cause mortality. However, use of nitrates, war-
farin, and anti-platelet agents were associated with an
increased risk of the primary end point. There was no as-
sociation between the use of beta-blockers or ACEI and
cardiovascular events or death. Those patients prescribed
cardioprotective medications had different baseline char-
acteristics than those not prescribed cardioprotective
medications. In addition, the associations we observed
were highly dependent on the outcome utilized.
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10. Secondary PVD (N = 723 events = 232) Fig. 1. Association between baseline use of
any calcium channel blocker (CCB) and vari-
ous outcomes.
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7. Primary CHF (N = 1784 events = 438)
8. Secondary CHF (N = 1260 events = 595)
9. Primary PVD (N = 2321 events = 472)
10. Secondary PVD (N = 723 events = 232) Fig. 2. Association between baseline use of
any angiotensin-converting enzyme inhibitor
(ACEI) and various outcomes.
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1. CVD or death (N = 3044 events = 2234)
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events = 2060)
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8. Secondary CHF (N = 1260 events = 595)
9. Primary PVD (N = 2321 events = 472)
10. Secondary PVD (N = 723 events = 232) Fig. 3. Association between baseline use of
any HMG-CoA reductase inhibitor (statin)
and various outcomes.
Calcium channel blockers and events
Using the same data set, but with a shorter duration
of follow-up, Kestenbaum et al [3] demonstrated that
CCB use was associated with a decreased mortality in in-
cident dialysis patients. We have demonstrated that CCB
use was associated with a decreased risk of cardiovas-
cular events or death, with much of the benefit driven
by a reduction in mortality. However, we were unable to
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Fig. 4. Association between baseline use of
any beta-blocker and various outcomes.
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Fig. 5. Association between baseline use of
any anti-platelet agent and various outcomes.
demonstrate that CCB use was associated with a decrease
in either a composite of cardiovascular events or in in-
dividual disease event rates. A possible explanation for
this discrepancy is that many individuals on dialysis die
sudden unwitnessed deaths. While these have previously
been assumed to be arrhythmic in nature, these deaths
may in fact be due to other cardiovascular disease (MIs
or CHF). Because these deaths occur at home, they are
not assigned a diagnosis, and Medicare bills are not gen-
erated. It is possible that sudden out-of-hospital death
was the initial cardiovascular event and was undetected
as such, leading to a lack of association between CCB
use and clinical cardiovascular events. This is plausible
because it is estimated that 26% of dialysis patients die
during their initial hospitalization for a MI [2]. It is un-
known what percent of those with cardiovascular events
never survive to hospitalization. Alternatively, these re-
sults may be the result of preferential treatment of low-
risk individuals with CCBs over other drugs. Baseline use
of CCBs was inversely associated with a previous MI his-
tory. The association between CCB use and a decrease
in all-cause mortality may be a true association; how-
ever, one must use caution in this conclusion until there
is validation of these findings from other data sets and
randomized controlled trials.
HMG-CoA reductase inhibitors and mortality
We were unable to demonstrate a benefit of statin use
on our a priori defined primary outcome. We were, how-
ever, able to demonstrate a protective association when
CHF events were excluded from our composite end point
and on all-cause mortality. These results are similar to
those previously published [6], which demonstrated that
statin use was associated with a reduction in mortality. It
has been well documented that statin therapy decreases
MIs, strokes, and mortality in the general population. Our
analysis appears to be very sensitive to the inclusion or
exclusion of CHF events in our primary outcome mea-
sure. In those without a previous history of CHF, there
appeared to be a trend increasing the risk for develop-
ing CHF on statin therapy. While only 10% of our cohort
was initially taking a statin-type drug, the distribution was
skewed toward those with a previous history of MIs. This
group of individuals is not only at increased risk for subse-
quent MIs, but also for CHF events, likely explaining our
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observation that statins are associated with an increased
risk for incident CHF events. Given this indication bias,
it is difficult to determine the true association between
statins and cardiovascular disease. A randomized, con-
trolled trial of statin use in dialysis patients should be
undertaken.
Other medications
We were unable to demonstrate an association between
ACEI use and study outcomes. This result may be true,
in that ACEI do not alter cardiovascular disease in dial-
ysis patients, or may be the result of biases that we were
unable to detect. The same conclusion may be drawn
for beta-blockers and events. However, we were able to
demonstrate that beta-blocker use was more common in
those with a previous MI history, making it difficult to
demonstrate a benefit.
We demonstrated that use of anti-platelet agents or
warfarin was associated with an increased number of car-
diovascular events and death. These associations were
similar when death was censored as an outcome. How-
ever, when individual diseases were assessed indepen-
dently the effect of these drugs on outcomes was variable.
The results for anti-platelet agents and warfarin are in di-
rect conflict with the results of clinical trials performed in
the general population, which have demonstrated a ben-
eficial effect of both medications in the secondary pre-
vention of cardiovascular events [11, 12]. In our study,
those prescribed anti-platelet agents or warfarin were
more likely to have cardiovascular disease at baseline
compared with those not taking these drugs. Addition-
ally, these drugs may have been used to prevent vascular
access complications, which may be a marker of future
cardiovascular events. These results suggest that there ei-
ther remains residual confounding, as those prescribed
these medications were at higher risk for outcomes, or
individuals on dialysis are different from the general pop-
ulation and these drugs are indeed associated with harm.
Our results are, therefore, unreliable, and it should not
be interpreted that these medications are associated with
poorer outcomes.
The associations we have demonstrated for drug ther-
apies appear to be variable, and dependent on the out-
come used. In addition, our results for statins, ACEI,
beta-blockers, and anti-platelet agents are significantly
different from previous randomized, controlled trials in
the general population [13, 14–16]. Using registry data
to determine an association between a therapy and out-
come appears to be fraught with confounding. Individ-
uals are not assigned drug therapies randomly but for
an underlying clinical indication, and while we have at-
tempted to correct for known confounders there likely
exists unmeasured, unknown, and unidentified factors
that are confounding our results. Additionally, we, and
others, have looked at multiple medications and their ef-
fect on outcomes without adjusting the level of statistical
significance. Had we done this, our results would have
changed dramatically and many of our significant associ-
ations would have disappeared. Specifically, we would not
have been able to demonstrate the protective association
between CCBs and our primary outcome measure if we
had used a cut-off of P = .01 (adjusted for 5 medications).
Given these issues, therapeutic associations from registry
studies must be confirmed through well-designed, ade-
quately powered, randomized, controlled trials, before
therapies are widely instituted.
Limitations
There are several limitations to our study. We have used
a prospective cohort of incident dialysis patients to define
associations between modifiable risk factors, medication
use, and cardiovascular outcomes. We have restricted our
analysis to those enrolled in the Medicare program, which
may have introduced some bias into our results. We at-
tempted to define major differences between those in-
cluded and excluded from our analysis. Compared with
those included, excluded individuals had similar baseline
characteristics aside from age, gender, and a previous his-
tory of MIs. Given these differences, we looked at out-
comes with and without excluded individuals. Mortality
appeared similar in both groups and was not influenced by
Medicare status. Additionally, our results for CCBs and
their effect on mortality are similar to those previously
published, in which the majority of Wave 2 participants
was used [3]. Additionally, while we have attempted to
correct for multiple confounders, we were not able to ad-
just for previously described dialysis-related cardiovas-
cular risk factors, such as parathyroid hormone, albumin,
or phosphorous, as numerous individuals had missing val-
ues for these results. A previous analysis of the Wave 2
study was unable to demonstrate a significant relationship
between many of these markers and acute coronary syn-
dromes [8]. Serum albumin was significantly associated
with both cardiovascular disease and death; however, due
to a large number of missing values and the lack of im-
pact on the hazard ratio of cardioprotective medications,
albumin was left out of the final multivariate model.
We were able to demonstrate that anti-platelet agents,
warfarin, or nitrate use associated with an increased car-
diovascular risk, while use of CCBs was associated with
a reduction in our composite end point and in all-cause
mortality. Statin use, while not associated with a reduc-
tion of our primary end point, was associated with a
reduction in overall mortality. We were unable to demon-
strate any association between ACEI or beta-blockers
and cardiovascular events. These findings may be con-
founded by reverse epidemiology. There should be a ran-
domized, controlled trial assessing the impact of common
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cardioprotective medications on cardiovascular out-
comes in dialysis patients.
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